Mankind Pharma Ltd

- The company plans to be conservative with cash usage. - Priority for cash utilization will be on M&A opportunities and CAPEX. - CAPEX planned for FY24 is around Rs. 500 to 600 crores. - No explicit mention of new fundraising through debt or equity in the current quarters. - Dividend payout decisions will be taken in the coming quarters based on cash position. - The company is generating strong cash flows (Rs. 2,000+ crores from operations) with a healthy net cash position of Rs. 1,727 crores as of March 2023. - No indication of immediate equity or debt issuance; focus remains on organic growth, CAPEX, and acquisitions using existing cash.

- The company has spent around Rs. 310 crores on the Udaipur plant, which is expected to be commercialized and capitalized in H1 FY24, leading to depreciation expenses in subsequent quarters. - For FY24, planned CAPEX is around Rs. 550 to Rs. 600 crores. - The Udaipur plant will house Dydrogesterone manufacturing, with no significant rise in OPEX expected. - The company remains conservative with cash but prioritizes investments in good M&A opportunities. - Excess cash generation (over Rs. 2,000 crores from operations) beyond CAPEX needs (Rs. 500-600 crores annually) is expected to be deployed strategically, possibly including acquisitions in Consumer Healthcare and chronic segments.

- Chronic segment expected to drive significant growth; chronic share reached all-time high of 36% with 17% growth this quarter, outperforming IPM growth of 10% by 1.7x. - Consumer Healthcare segment projected to sustain strong growth, with 8% Q1 growth and historic CAGR of 22% (FY21-23). - Aim to launch 15-20 new DMF-grade SKUs every quarter, targeting disruptive growth via high-quality, affordable medicines. - Domestic business will continue contributing over 90% of revenues; export business remains a smaller portion with lower margins. - Focus on volume-led growth through wide distribution and prescription-led sales with 5 lakh doctors covered. - Expect to maintain EBITDA margins in the range of 24%-26%. - Continued investment in marketing and R&D to support leadership in chronic and Consumer Healthcare segments. - Overall volume growth in the domestic market significantly outpacing IPM growth (4.3% vs 1.4% in Q1).

- EBITDA margins guidance for FY24 is maintained at 24% to 26% (Page 13, 7). - Management is confident of maintaining or improving EBITDA margins beyond FY24 due to operating leverage and mix improvement (Page 7). - Chronic segment share is increasing (36% in Q1 FY24 vs 28% in FY18), expected to outperform the market and drive higher margins (Page 6, 15). - Volume-led growth with superior prescription-driven quality sales is sustainable and expected to continue (Page 5-6). - PAT grew 66% YoY to Rs. 494 crore in Q1 FY24; EPS was Rs. 12.1 per share, with cash EPS at Rs. 14.3 (Page 7). - CAPEX planned in the range of Rs. 550-600 crore in FY24 supports growth ambitions (Page 7, 12). - Export business growth is opportunistic but domestic business will continue to contribute >90% revenues (Page 10, 15).

The transcript does not provide any specific information regarding the current or expected order book or pending orders for Mankind Pharma Limited in Q1 FY24. There are no mentions of order backlog, pending orders, or order book figures in the discussed content on page 15 or surrounding pages. The focus is mainly on financial results, growth in domestic and export revenues, chronic segment expansion, margins, and operational metrics.